Kushnir M, et al. - In this single-center, retrospective analysis, researchers looked at the effectiveness and safety of apixaban and rivaroxaban in morbidly obese patients relative to that of warfarin. The study was conducted at Montefiore Medical Center (Bronx, NY) and included patients aged at least 18 years of age with a body-mass index of at least 40 kg/m² and received apixaban, rivaroxaban, or warfarin for either venous thromboembolism or atrial fibrillation. Data analysis was done for 795 patients (150 received apixaban, 326 rivaroxaban, and 319 warfarin). In morbidly obese patients with atrial fibrillation and venous thromboembolism, the direct oral anticoagulants apixaban and rivaroxaban had effectiveness and safety similar to that of warfarin in this study.